Results 81 to 90 of about 16,088 (196)

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

Experimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu, Xingyu Qiu, Nan Xu, Gensheng Zhang, Enyin Lai, Liang Zhao   +5 more
wiley   +1 more source

Dietary interventions in acute kidney injury: From molecular mechanism to clinical trials

Experimental Physiology, EarlyView.
Abstract Ageing impairs renal resilience with an elevated risk of frequent and harmful acute kidney injury (AKI) that causes substantial morbidity and mortality among hospitalized patients. Since different damaging stimuli at the molecular, cellular and functional level contribute to this loss in kidney function, AKI's pathophysiology is heterogeneous ...
Felix C. Koehler, Pedro Rojas‐Morales, Roman‐Ulrich Müller   +2 more
wiley   +1 more source

Renal replacement therapy in acute kidney injury: controversy and consensus [PDF]

, 2015
Renal replacement therapies (RRTs) represent a cornerstone in the management of severe acute kidney injury. This area of intensive care and nephrology has undergone significant improvement and evolution in recent years.
A Davenport, A Link, A Tolwani, A Vijayan, A Zarjou, AA House, AC Pont de, AG Schneider, AN Berbece, AW Holt, B Manns, BA Bart, BE Zacharia, C Clec’h, C Forster, C Lanckohr, C Ronco, C Ronco, C Ronco, C Ronco, CF Weber, CJ Karvellas, Claudio Ronco, D Cheyron du, D Morgan, D Payen, D Payen, D Payen, D Ward, DA Geerse, Daniel De Backer, Didier Payen, DM Roberts, DN Cruz, DN Cruz, E Lindhoff-Last, EA Hoste, F Zhou, Fabio S Taccone, Franco Turani, FS Taccone, GF Lehner, GR Hetzel, H Kushi, HM Oudemans-van Straaten, HM Oudemans-van Straaten, HM Oudemans-van Straaten, HR Chua, HR Geus de, I Baldwin, IF Btaiche, J Benz-Worner, J Hirsh, J Mishra, J Wetering van de, JA Jamal, JA Kelleher, JA Kellum, Jean-Louis Vincent, JJ Parienti, JJ Parienti, John A Kellum, John R Prowle, JT Kielstein, K Damman, K Selleng, Kidney Disease Outcomes Quality Initiative, L Corral, L Gabutti, L Schilder, L Seyler, LS Chawla, M Beumier, M Beumier, M Greaves, M Gritters, M Haase, M Hemmer, M Hites, M Joannidis, M Joannidis, M Legrand, M Liu, M Patarroyo, Massimo Antonelli, Michael Joannidis, MR Costanzo, N Lameire, N Srisawat, N Srisawat, N Srisawat, NK Burki, O Joannes-Boyau, Olivier Joannes-Boyau, P Zhang, Patrick Saudan, Peter Pickkers, PH Voort van der, PH Voort van der, PM Honore, PM Palevsky, R Atan, R Atan, R Bellomo, R Bellomo, R Bellomo, R Bellomo, R Faulhaber-Walter, R Murugan, R Murugan, R Wald, Rinaldo Bellomo, RP Dellinger, S Blot, S Bournazos, S Hiremath, S Livigni, S Morabito, S Uchino, SB Ko, TH Kiser, TH Kiser, TS Hoke, TT Leite, V Cantaluppi, V Schwenger, VA Kumar, VC Wu, VC Wu, Vincenzo Cantaluppi, W Mullens, X Wen, Z Ricci, Z Ricci, Zaccaria Ricci   +134 more
core   +5 more sources

Mitochondrial Transplantation as a New Therapeutic Approach Against Cardiac and Renal Consequences in Male Rats With Myocardial Infarction

Acta Physiologica, Volume 242, Issue 6, June 2026.
ABSTRACT Aim Myocardial infarction (MI) is one of the leading causes of death worldwide. MI is associated with cardiac structural and functional alterations. Among these, cardiac fibrosis may be significantly influenced by mitochondrial dysfunction. We sought to evaluate whether the injection of functional mitochondria from healthy muscle could improve
María Cuesta‐Corral, Alejandro Montoro‐Garrido, Ana Romero‐Miranda, Fabián Islas, Bunty Ramchandani, Ricardo Gredilla, Joaquín Fernández‐Irigoyen, Enrique Santamaría, Beatriz Delgado‐Valero, Sara Jiménez‐González, Raquel Rodrigues Díez, María Luisa Nieto, Victoria Cachofeiro, Ernesto Martínez‐Martínez   +13 more
wiley   +1 more source

Cardiorenal Syndrome in Acute Heart Failure Syndromes

International Journal of Nephrology, 2011
Impaired cardiac function leads to activation of the neurohumoral axis, sodium and water retention, congestion and ultimately impaired kidney function. This sequence of events has been termed the Cardiorenal Syndrome.
Mohammad Sarraf, Robert W. Schrier
doaj   +1 more source

Cardiorenal Syndrome Type 4—Cardiovascular Disease in Patients with Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management [PDF]

, 2011
The term cardiorenal syndrome refers to the interaction between the heart and the kidney in disease and encompasses five distinct types according to the initial site affected and the acute or chronic nature of the injury.
Panagiotis Pateinakis, Aikaterini Papagianni   +1 more
core   +1 more source

Efficacy and Safety of Fixed‐Dose Combinations of Sitagliptin and Empagliflozin as Add‐On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Multi‐Centre, Placebo‐Controlled, Phase III Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4847-4859, June 2026.
ABSTRACT Background Type 2 diabetes mellitus (T2DM) is a progressive, multi‐organ disorder that often requires intensive combination therapy. This Phase III, randomised, double‐blind, placebo‐controlled study evaluated the efficacy and safety of two fixed‐dose combinations (FDCs) of sitagliptin 100 mg with empagliflozin 10 mg (DW1026C1) or ...
Soo Lim, Tae Nyun Kim, Ji Oh Mok, Choon Hee Chung, You Cheol Hwang, Ho Chan Cho, Jong Chul Won, Eonju Jeon, Eun Seok Kang, Ki Young Lee, Chong Hwa Kim, Soo Heon Kwak, Cheol Young Park, Kang Seo Park, Sang Yong Kim, Jae Hyuk Lee, Soon Hee Lee, Dong Hyeok Cho, Hyuk‐Sang Kwon, Kyung Ah Han   +19 more
wiley   +1 more source

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5163-5173, June 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used for the treatment of type 2 diabetes, yet their downstream consequences in routine clinical practice remain incompletely characterized.
Yazan Alhamdan, Jason C. Hsu, Christine Y. Lu   +2 more
wiley   +1 more source

Improving Prognosis Estimation in Patients with Heart Failure and the Cardiorenal Syndrome

International Journal of Nephrology, 2011
The coexistence of heart failure and renal dysfunction constitutes the “cardiorenal syndrome” which is increasingly recognized as a marker of poor prognosis.
Husam M. Abdel-Qadir, Shaan Chugh, Douglas S. Lee   +2 more
doaj   +1 more source

Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. [PDF]

, 2011
Little is known about the effect of anemia correction with erythropoietin (EPO) on B-type natriuretic peptide (BNP) levels, NYHA class, and hospitalization rate.
Antonelli, G, Calabrò, A, Campagna, Ms, Caputo, M, Franci, B, Nuti, R, Palazzuoli, A, Quatrini, I   +7 more
core   +1 more source